A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom

• Status: Completed
• Trial end date: 2015-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the impact of escitalopram on quality of life and social functionality in patients with major depressive disorder with anxiety symptom.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xian-Janssen Pharmaceutical Ltd.
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• Diagnosis of major depressive disorder according to the American Psychiatric Association's Diagnostic and Statistical Manual-IV, Text Revision (DSM-IV-TR) diagnostic criteria

• Minimum scores of 9 on Sheehan Disability Scale

• Minimum scores of 14 on Hamilton Anxiety Scale

Exclusion Criteria:

• History of primary or comorbid diagnoses of schizophrenia, schizoaffective disorder, bipolar disorder, or dementia

• Presence of unstable serious illness and/or has a clinically significant renal or hepatic impairment, seizure disorders or any other disease which may be detrimental to the participant or the study

• Participant who have continuously taken psychoactive substances, antidepressants, anxiolytics, Monoamine oxidase inhibitors, psychoactive herbal remedies, lithium, electroconvulsive therapy, carbamazepine in the past 2 weeks before the baseline visit

• Diagnosis of major depressive disorder who currently require treatment systematically within past 2 months from baseline

• Receiving pharmacological treatment, which is disallowed in the current approved Chinese summary of product characteristics for escitalopram